Related Experiment Videos
Interferon-alpha prevents endotoxin-induced mortality in mice
1Department of Medicine, Veterans Administration Medical Center, Buffalo, NY 14215.
European Journal of Immunology
|December 1, 1992
Summary
Recombinant human hybrid interferon-alpha A/D (rIFN-alpha) significantly improved survival in mice challenged with endotoxin (lipopolysaccharide, LPS). Early or delayed rIFN-alpha administration reduced tumor necrosis factor (TNF) production and protected against lethal endotoxemia.
Area of Science:
- Immunology
- Pharmacology
- Microbiology
Background:
- Endotoxins (lipopolysaccharide, LPS) from Gram-negative bacteria cause severe septicemia.
- Tumor necrosis factor (TNF), produced by macrophages, mediates LPS-induced pathology.
- Kupffer cells are key macrophages involved in the LPS response.
Purpose of the Study:
- To investigate the therapeutic potential of recombinant human hybrid interferon-alpha A/D (rIFN-alpha) in endotoxemia.
- To assess the effect of rIFN-alpha on LPS-induced TNF production and survival in mice.
Main Methods:
- In vitro: Kupffer cells were stimulated with LPS, and TNF production was measured with and without rIFN-alpha.
- In vivo: C57BL/6 mice received lethal LPS doses, with varying timings of rIFN-alpha administration (pretreatment or post-treatment).
- Survival rates, TNF mRNA expression in liver and spleen, and plasma TNF levels were assessed.
Main Results:
- rIFN-alpha inhibited LPS-induced TNF production by Kupffer cells in vitro.
- Post-treatment with rIFN-alpha 20 minutes after LPS significantly increased mouse survival (81%).
- Delayed administration of rIFN-alpha, even up to 14 hours after LPS, still conferred significant protection.
Conclusions:
- rIFN-alpha demonstrates significant therapeutic potential for endotoxemia.
- The protective effects extend beyond initial TNF production inhibition, suggesting multiple mechanisms.
- rIFN-alpha offers a promising strategy for preventing and treating endotoxin-induced damage.